key: cord-0795851-5n7r20pc
authors: Youssef, Soundos; Lavian, Jonathan; Lee, Eunice Y.; Fan, Weijia; Bordone, Lindsey A.
title: Tofacitinib Therapy for Alopecia Areata is not Associated with Adverse Events during COVID-19 Infection
date: 2022-05-10
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2022.05.005
sha: b5a58eeca433151cb1c2fba339549c76fe1828db
doc_id: 795851
cord_uid: 5n7r20pc

nan

to preclude its immunosuppressive effect and due to high mortality rate and global burden of COVID-19 43 [3] . We thus aimed to retrospectively evaluate how oral tofacitinib among AA patients affected clinical 44 outcomes (hospitalization, oxygen supplementation, intensive care unit (ICU) admission) after controlling 45 for baseline AA patient characteristics. We queried for patients with ICD 10 codes L63.9 (AA) and U07.1 46 (COVID-19 infection) from 3/1/20 to 10/31/21 using our Clinical Data Warehouse. We previously validated 47 that patients with an ICD code for AA are highly likely to have a true diagnosis of AA [4]. We identified 48 1,405 patients with AA who sought healthcare during the time span. Among the 1,405 patients, there 49 were 73 chart-documented COVID-19 AA cases. Among these 73 patients, there were 29 tofacitinib-50 treated (TT) and 44 treatment-naïve (TN) AA patients. All 29 TT patients were on 10 mg twice a day dosing. 51

We controlled for variables known to lead to a worse outcome among COVID-19 patients (Table 1) [5]. 52

Demographic and clinical characteristics of TT and TN AA were analyzed using Fisher's exact and Kruskal-53

Wallis tests for categorical and continuous variables respectively at a significance level of 0.05 (Table 1) . 54

Infection clinical outcome odds ratio estimates were reported at a 95% confidence interval in Table 2 . 55 vs 0%, p=0.009) in TN AA. No TT AA patient had deterioration (hospitalization, oxygen requirement, ICU 60 admission) in infection course. In the TN AA cohort, 5/44 were hospitalized (2 on oxygen nasal cannula, 1 61 intubated for 3 days, and 1 intubated with complicated ICU course). In our small and limited cohort, there 62 was no signal that tofacitinib led to worse outcomes and conversely may have a protective effect. Given 63 these findings, larger cohort studies are necessary to determine whether providers should be advising 64 patients diagnosed with COVID-19 to withhold tofacitinib treatment and whether current 65 recommendations may be harmful [3] . Larger scale studies are needed to delineate the long-term safety 66 profile of oral tofacitinib in AA. 

Evaluation of the alopecia areata patients on 83 tofacitinib treatment during the COVID-19 pandemic

Identification for Alopecia Areata Using International Classification of Diseases Coding

Population risk factors 90 for severe disease and mortality in COVID-19: A global systematic review and meta-analysis